Evofem BiosciencesEVFM -6.07% Days Payable is 2,799.37 as of Mar. 2026, which is 154% above its 10-year median of 1,102.48. The stock has 5 warning signs investors should review. Among 706 Biotechnology companies, Evofem Biosciences ranks better than 85.41% on this metric.
The historical rank and industry rank for Evofem Biosciences's Days Payable or its related term are showing as below:
EVFM'
s Days Payable Range Over the Past 10 Years
Min: 896.92 Med: 1102.48 Max: 6492.4
Current: 944.13
During the past 13 years, Evofem Biosciences's highest Days Payable was 6492.40. The lowest was 896.92. And the median was 1102.48.
EVFM's Days Payable is ranked better than 85.41% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs EVFM: 944.13
Evofem Biosciences's Days Payable
declined
from Mar. 2025 (3,424.50) to Mar. 2026 (2,799.37).
It may suggest that Evofem Biosciencesaccelerated paying its suppliers.
Evofem Biosciences Days Payable Related Terms
Evofem Biosciences Days Payable Historical Data
* Premium members only.
The historical data trend for Evofem Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Evofem Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evofem Biosciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Evofem Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Evofem Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evofem Biosciences (EVFM) has a Days Payable of 2,799.37 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Evofem Biosciences and its competitors. This is 154% above median its historical median of 1,102.48. Over the past decade, Evofem Biosciences' Days Payable has ranged from 896.92 to 6,492.40. According to the industry distribution chart, Evofem Biosciences ranks #103 out of 706 companies in the Biotechnology industry, placing it in the top 14.6%.
Is Evofem Biosciences' Days Payable too high?
Evofem Biosciences' current Days Payable of 2,799.37 is 154% above median its 10-year median of 1,102.48. Over the past 10 years, this metric has ranged from a low of 896.92 to a high of 6,492.40. The Biotechnology industry median Days Payable is 113.56. Evofem Biosciences' value of 2,799.37 is 2365.1% above this industry median. Based on the distribution chart, Evofem Biosciences ranks #103 out of 706 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Evofem Biosciences' Days Payable compare to PTIX and ATXI?
According to the Biotechnology industry distribution chart, Evofem Biosciences ranks #103 out of 706 companies for Days Payable. This places Evofem Biosciences in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Evofem Biosciences' value of 2,799.37 is 2365.1% above this benchmark. Historically, Evofem Biosciences' own Days Payable has ranged from 896.92 to 6,492.40 over the past decade. While the company's 10-year median is 1,102.48 vs. the industry median of 113.56, Evofem Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evofem Biosciences's current Days Payable of 2,799.37 is 2365.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Evofem Biosciences and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evofem Biosciences's current Days Payable is 2,799.37, which is 154% above median its own 10-year median of 1,102.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 18% below its estimated fair value. The current Days Payable is 2,799.37, which is 154% above median its 10-year median of 1,102.48 and 2365.1% above the Biotechnology industry median of 113.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Days Payable is 2,799.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVFM has been successfully added to your 